Selective CYP17 inhibition with abiraterone acetate (AA) in castration resistant prostate cancer (CRPC): the Royal Marsden Hospital experience

被引：0
|
作者：
Reid, A. [1 ]
Attard, G. [1 ]
Oommen, N. Babu [1 ]
Olmos, D. [1 ]
Fong, P. [1 ]
Molife, R. [1 ]
Dowsett, M. [2 ]
Lee, G. [3 ]
Molina, A. [3 ]
De-Bono, J. S. [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Drug Dev Unit, London, England
[2] Acad Dept Biochem, Royal Marsden NHS Fdn Trust, London, England
[3] Cougar Biotechnol Inc, Los Angeles, CA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)71958-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC).
    Attard, Gerhardt
    Reid, Alison H. M.
    Sinha, Rajesh
    Molife, Rhoda
    Raynaud, Florence
    Dowsett, Mitch
    Barrett, Mary
    Thompson, Emilda
    Yap, Timothy A.
    Settatree, Sarah
    Martins, Vanessa
    Parker, Christopher
    Dearnaley, David
    Folkerd, Elizabeth
    Lee, Gloria
    De Bono, Johann S.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3455S - 3455S
  • [2] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Attard, Gerhardt
    Reid, Alison H. M.
    A'Hern, Roger
    Parker, Christopher
    Oommen, Nikhil Babu
    Folkerd, Elizabeth
    Messiou, Christina
    Molife, L. Rhoda
    Maier, Gal
    Thompson, Emilda
    Olmos, David
    Sinha, Rajesh
    Lee, Gloria
    Dowsett, Mitch
    Kaye, Stan B.
    Dearnaley, David
    Kheoh, Thian
    Molina, Arturo
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3742 - 3748
  • [3] Re: Selective Inhibition of CYP17 with Abiraterone Acetate is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
    Schmid, Hans-Peter
    Engeler, Daniel S.
    EUROPEAN UROLOGY, 2009, 56 (04) : 744 - 745
  • [4] Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC)
    De Bono, J. S.
    Attard, G.
    Reid, A. H.
    Parker, C.
    Dowsett, M.
    Mollife, R.
    Yap, T. A.
    Molina, A.
    Lee, G.
    Dearnaley, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] SAFETY OF ABIRATERONE ACETATE (AA) IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND CONCOMITANT CARDIAC RISK
    Procopio, G.
    Verzoni, E.
    Testa, I.
    Stagni, S.
    Villa, S.
    Valdagni, R.
    De Braud, F. G. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 305 - 305
  • [6] A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).
    Mckay, Rana R.
    Werner, Lillian
    Jones, Alexandra
    Choudhury, Atish Dipankar
    Pomerantz, Mark
    Sweeney, Christopher
    Bubley, Glenn J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Abiraterone acetate (AA), an irreversible inhibitor of CYP17, has significant and durable anti-tumor activity in both chemotherapy-naive and docetaxel treated castration-resistant prostate cancer (CRPC)
    Attard, G.
    Reid, A.
    Oommen, N. Babu
    Folkerd, L.
    Olmos, D.
    Thompson, E.
    Maier, G.
    Dowsett, M.
    Dearnaley, D.
    De Bono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 51 - 51
  • [8] Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer
    Bedoya, Diego J.
    Mitsiades, Nicholas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (01) : 1 - 3
  • [9] Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
    Reid, Alison H. M.
    Attard, Gerhardt
    Danila, Daniel C.
    Oommen, Nikhil Babu
    Olmos, David
    Fong, Peter C.
    Molife, L. Rhoda
    Hunt, Joanne
    Messiou, Christina
    Parker, Christopher
    Dearnaley, David
    Swennenhuis, Joost F.
    Terstappen, Leon W. M. M.
    Lee, Gloria
    Kheoh, Thian
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric
    Scher, Howard I.
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1489 - 1495
  • [10] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    Attard, Gerhardt
    Reid, Alison H. M.
    Yap, Timothy A.
    Raynaud, Florence
    Dowsett, Mitch
    Settatree, Sarah
    Barrett, Mary
    Parker, Christopher
    Martins, Vanessa
    Folkerd, Elizabeth
    Clark, Jeremy
    Cooper, Colin S.
    Kaye, Stan B.
    Dearnaley, David
    Lee, Gloria
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) : 4563 - 4571
12345